Add this topic to your myFT Digest for news straight to your inbox
Japan Investment Corporation’s $6.4bn offer for JSR comes as governments seek to protect semiconductor technology
Evobrutinib would have more than compensated for falling sales from German group’s existing medicines
Evobrutinib failed to reduce relapse rates compared with teriflunomide, produced by rival Sanofi
Pharmaceutical group employs services of Spot to carry out checks at incineration plants
German group scuppers deal agreed with Entegris of the US
Life sciences group ramps up efforts to frustrate Entegris’s all-stock deal
German group hopes to boost performance materials unit after making counter bid
Some companies pledge to lower costs if government reforms rebate system
Politicians to grill pharma executives over what is fast becoming a key election issue
Drugs groups are investing heavily in analytics but deals do not always prosper
Deal will increase presence in biggest over-the-counter healthcare markets
Merck decision to explore divisional sale sparks debate over merits of OTC businesses
Approval for immunotherapy treatment a rare win for R&D pipeline
UK High Court rules North American group has infringed rights
German group seeks to tap into continent’s shifting disease patterns
German drugmaker hopes to strengthen claim to 347-year-old family name shared by US rival
Drugmaker’s change of leadership comes as it looks to bet on a new generation of cancer treatments
Bill Gross is among the big fund managers trying new strategies
Immunotherapy moves out of clinical trials and into real world use
‘Immunotherapy’ treatments turn the body’s immune system into a weapon against disease
International Edition